Literature DB >> 11819732

Inhibition of hepatitis B virus by oxymatrine in vivo.

X S Chen1, G J Wang, X Cai, H Y Yu, Y P Hu.   

Abstract

AIM: To investigate the anti-HBV effect of oxymatrine (oxy) in vivo.
METHODS: HBV transgenic mice were produced by micro-injection of a 4.2 kb fragment containing the complete HBV genomes. Expression level of HBsAg and HBcAg in the transgenic mice liver was determined by immunohistochemical assay.
RESULTS: Four groups (6 mice in each group) were injected intraperitoneally with oxy at the dosage of 100, 200, and 300 mg/kg or with saline once a day for 30 days. Both HBsAg and HBcAg were positive in livers of all the six mice in the control group (injected with saline), and were positive in livers of two mice in 100mg/kg group and 300 mg/kg group. In 200 mg/kg group, HBsAg and HBcAg were negative in livers of all the six mice. Based on the results, 200mg/kg is the ideal dosage to explore the effect of oxy at different time points. According to the oxy treatment time, mice were divided into four groups: 10 d, 20 d, 30 d and 60 d (4 mice in each group). Each mouse underwent liver biopsy two weeks before the treatment of oxy. Down-regulation of HBsAg and HBcAg appeared after treatment of oxymatrine for 10 d and 20 d, Dane-like particles disappeared after the treatment of oxy for 20 d under electron microscopy, however, the expression level of HBsAg and HBcAg returned to normal 60 d later after oxy treatment.
CONCLUSION: Oxymatrine can reduce the contents of HBsAg and HBcAg in transgenic mice liver,longer treatment time and larger dosage do not yield better effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11819732      PMCID: PMC4688700          DOI: 10.3748/wjg.v7.i1.49

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  17 in total

1.  Clinical study on the treatment of liver fibrosis due to hepatitis B by IFN-alpha(1) and traditional medicine preparation.

Authors:  Ming-Liang Cheng; Ya-Yun Wu; Ke-Fu Huang; Tian-Yong Luo; Yi-Shen Ding; Yin-Yin Lu; Ren-Cai Liu; Jun Wu
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

2.  Detection of HBV DNA and its existence status in liver tissues and peripheral blood lymphocytes from chronic hepatitis B patients.

Authors:  Ren-Xian Tang; Feng-Guang Gao; Ling-Yu Zeng; Ying-Wei Wang; Yu-Long Wang
Journal:  World J Gastroenterol       Date:  1999-08       Impact factor: 5.742

3.  [Effects of oxymatrine on the antitumor activity and toxicity of cyclophosphamide in mice].

Authors:  C Yuan; S Q Lu; X Yao
Journal:  Yao Xue Xue Bao       Date:  1987-04

4.  Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B.

Authors:  J H Hoofnagle; M Peters; K D Mullen; D B Jones; V Rustgi; A Di Bisceglie; C Hallahan; Y Park; C Meschievitz; E A Jones
Journal:  Gastroenterology       Date:  1988-11       Impact factor: 22.682

5.  Interleukin-12 inhibits hepatitis B virus replication in transgenic mice.

Authors:  V J Cavanaugh; L G Guidotti; F V Chisari
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

6.  Hepatitis B virus replication is cell cycle independent during liver regeneration in transgenic mice.

Authors:  L G Guidotti; B Matzke; F V Chisari
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

7.  Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver.

Authors:  L G Guidotti; P Borrow; M V Hobbs; B Matzke; I Gresser; M B Oldstone; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

8.  Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a posttranscriptional mechanism.

Authors:  S Guilhot; L G Guidotti; F V Chisari
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

9.  A transgenic mouse model of the chronic hepatitis B surface antigen carrier state.

Authors:  F V Chisari; C A Pinkert; D R Milich; P Filippi; A McLachlan; R D Palmiter; R L Brinster
Journal:  Science       Date:  1985-12-06       Impact factor: 47.728

10.  Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice.

Authors:  V J Cavanaugh; L G Guidotti; F V Chisari
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

View more
  29 in total

1.  Construction and characterization of an experimental ISCOMS-based hepatitis B polypeptide vaccine.

Authors:  Xiao-Ju Guan; Xiao-Jun Guan; Yu-Zhang Wu; Zheng-Cai Jia; Tong-Dong Shi; Yan Tang
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

2.  Oxymatrine triggers apoptosis by regulating Bcl-2 family proteins and activating caspase-3/caspase-9 pathway in human leukemia HL-60 cells.

Authors:  Jun Liu; Yazhou Yao; Huifang Ding; Renan Chen
Journal:  Tumour Biol       Date:  2014-02-23

3.  The analgesic effect and mechanism of the combination of sodium ferulate and oxymatrine.

Authors:  Hanqing Liu; Yan Sun; Yan Gao; Fangfang Chen; MingBo Xu; Zhifeng Liu
Journal:  Neurochem Res       Date:  2010-06-03       Impact factor: 3.996

Review 4.  Prevalence and current therapy in chronic liver disorders.

Authors:  Muhammad Daniyal; Muhammad Akram; Rida Zainab; Naveed Munir; Aamir Sharif; Syed Muhammad Ali Shah; Bin Liu; Wei Wang
Journal:  Inflammopharmacology       Date:  2019-02-08       Impact factor: 4.473

5.  Boosting immune response to hepatitis B DNA vaccine by coadministration of Prothymosin alpha-expressing plasmid.

Authors:  Yanwen Jin; Cheng Cao; Ping Li; Xuan Liu; Wei Huang; Chufang Li; Qingjun Ma
Journal:  Clin Diagn Lab Immunol       Date:  2005-12

Review 6.  Complementary and alternative medications in hepatitis C infection.

Authors:  Dina L Halegoua-De Marzio; Jonathan M Fenkel
Journal:  World J Hepatol       Date:  2014-01-27

7.  Oxymatrine attenuates intestinal ischemia/reperfusion injury in rats.

Authors:  Jinpeng Zhao; Shoujiang Yu; Liquan Tong; Feng Zhang; Xian Jiang; Shangha Pan; Hongchi Jiang; Xueying Sun
Journal:  Surg Today       Date:  2008-09-27       Impact factor: 2.549

Review 8.  Nanotechnology applications for the therapy of liver fibrosis.

Authors:  Lydia Giannitrapani; Maurizio Soresi; Maria Luisa Bondì; Giuseppe Montalto; Melchiorre Cervello
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

9.  Sequential changes of serum ferritin levels and their clinical significance in lamivudine-treated patients with chronic viral hepatitis B.

Authors:  Zheng-Wen Liu; Qun-Ying Han; Ni Zhang; Wen Kang
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

10.  Oxymatrine liposome attenuates hepatic fibrosis via targeting hepatic stellate cells.

Authors:  Ning-Li Chai; Qiang Fu; Hui Shi; Chang-Hao Cai; Jun Wan; Shi-Ping Xu; Ben-Yan Wu
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.